Begin main content

Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost-Effectiveness

Last updated: October 16, 2017
Project Number: RC0934-000
Product Line: Rapid Response
Research Type: Other Diagnostics
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the comparative clinical utility of gene expression tests to either predict adjunct chemotherapy or evaluate cancer recurrence risk in women with early stage breast cancer?
  2. What is the comparative cost-effectiveness of gene expression tests to either predict adjunct chemotherapy or evaluate cancer recurrence risk in women with early stage breast cancer?

Key Message

One moderate quality comparative clinical study provided evidence to suggest that Oncotype DX and EndoPredict were both prognostic for the risk of distant recurrence in the years zero through five. In years five through 10 EndoPredict was better able to predict distant recurrence compared to Oncotype DX. In comparisons between the high/non-low and the low risk groups, the hazard ratio was higher for EndoPredict.One moderate quality comparative cost-effectiveness study determined that the use of Mammostrat was more cost-effective and was associated with a cost savings of $2,268 per patient compared to Oncotype DX.